Healthcare Sales & Marketing Network News: ABILIFY

Searching News Database: ABILIFY

HSMN NewsFeed - 13 Nov 2019
Otsuka Announces Retirement of President & Chief Executive Officer William H. Carson, M.D.
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Feb 2019
SK Biopharmaceuticals and Arvelle Therapeutics Announce Agreement to Develop and Commercialize Cenobamate in Europe
Biopharmaceuticals Licensing

HSMN NewsFeed - 30 Jul 2018
OncoSec Appoints Robert W. Ashworth, Ph.D. as Vice President, Regulatory
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 22 Jun 2017
Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 3 Apr 2017
aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 Sep 2014
Dimension Therapeutics Names Annalisa Jenkins as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Jun 2014
Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Jan 2014
Osiris Therapeutics Board Confirms Lode Debrabandere, PhD, MBA, as President and Chief Executive Officer
Biopharmaceuticals Regenerative Medicine Personnel

HSMN NewsFeed - 5 Dec 2013
Tyrosine Pharma Names Laslie President and CEO
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 21 Nov 2013
Otsuka and Lundbeck's Once-Monthly Abilify Maintena(R) (Aripiprazole) Now Approved in Europe for Maintenance Treatment of Schizophrenia in Adult Patients Stabilized with Oral Aripiprazole
Biopharmaceuticals Regulatory

HSMN NewsFeed - 22 Oct 2012
Osiris Therapeutics Names Lode Debrabandere Chief Operating Officer
Regenerative Medicine Wound Care Personnel

HSMN NewsFeed - 16 Nov 2010
Otsuka Prevails in U.S. Abilify(R) Patent Litigation
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 25 Oct 2010
Omeros Receives $20 Million from Vulcan Capital and $5 Million Grant Award from Washington State's Life Sciences Discovery Fund to Advance its GPCR Program
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 5 May 2009
CytRx Appoints Jaisim Shah Chief Business Officer and Senior Vice President of Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Feb 2009
Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Apr 2008
Bristol-Myers Squibb and Otsuka Receive European Marketing Authorisation for ABILIFY(R) in the Treatment and Prevention of Moderate to Severe Manic Episodes in Bipolar I Disorder
Biopharmaceuticals Regulatory

HSMN NewsFeed - 29 Feb 2008
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Nov 2007
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Nov 2007
ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Nov 2007
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Oct 2007
Pediatric Asthma Programs With CyDex Captisol Technology Acquired by AstraZeneca
Biopharmaceuticals Drug Delivery Acquisitions

HSMN NewsFeed - 6 Sep 2007
Aradigm and CyDex Sign Development Collaboration Agreement
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 17 Jul 2007
ABILIFY(R) (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder
Biopharmaceuticals FDA

HSMN NewsFeed - 21 May 2007
Galenea Corp. Appoints Mark Benjamin as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Mar 2007
Barr Confirms Filing an Application with a Paragraph IV Certification for ABILIFY(R) Tablets
Biopharmaceuticals Generics

HSMN NewsFeed - 27 Dec 2006
Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive Licensing Agreement for Diabetes Compound Saxagliptin in Japan
Biopharmaceuticals Endocrinology Licensing

HSMN NewsFeed - 14 Dec 2006
CyDex Announces Captisol Technology Used in Recently Launched Injection Formulation of Antipsychotic Medication ABILIFY(R) (aripiprazole)
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 12 Dec 2006
ABILIFY(R) (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available
Biopharmaceuticals

HSMN NewsFeed - 7 Dec 2006
ABILIFY(R) (aripiprazole) Demonstrated Efficacy as Long-Term Maintenance Therapy in Adults With Bipolar I Disorder Following Treatment for a Recent Manic Or Mixed Episode
Biopharmaceuticals

HSMN NewsFeed - 14 Nov 2006
Bristol-Myers Squibb Company Announces Promotion of Andrew Bonfield and Elliott Sigal to Executive Vice Presidents
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jun 2006
Alpharma Names Dean J. Mitchell President and CEO
Biopharmaceuticals Personnel

HSMN NewsFeed - 16 May 2006
ABILIFY(R) (Aripiprazole) Demonstrated Efficacy as Maintenance Therapy In Adults with Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode
Biopharmaceuticals

Return to NewsFeed

Additional items found! 21

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 21 additional stories matching:
ABILIFY
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.